• Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type).

• Tumor staged as T3-4N1/N2-3 (according to the 8th American Joint Commission on Cancer edition).

• No evidence of distant metastasis (M0). Satisfactory performance status: Karnofsky scale (KPS) \> 70. Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL.

• Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \<1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.

• Adequate renal function: creatinine clearance ≥60 ml/min. Patients must be informed of the investigational nature of this study and give written informed consent.

• unsatisfactory tumor response (stable or progressive disease) after neoadjuvant chemotherapy (NACT)